Vaccines and therapeutics for the encephalitic alphaviruses

Future Virology

Volumn 8, Issue 7, 2013, Pages 661-674

  Nagata, Les P ^a   Wong, Jonathan P ^a   Hu, Wei Gang ^a   Wu, Josh Q ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

alphaviruses; antibodies; antivirals; eastern equine encephalitis; immune modulators; vaccines; Venezuelan equine encephalitis; western equine encephalitis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA INTERFERON; CONSENSUS INTERFERON; DELTA INTERFERON; DNA VACCINE; EPSILON INTERFERON; GAMMA INTERFERON; GLYCOPROTEIN E1; INTERFERON; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; KAPPA INTERFERON; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA; RINTATOLIMOD; SMALL INTERFERING RNA; THETA INTERFERON; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CHILDHOOD DISEASE; DRUG EFFICACY; EASTERN EQUINE ENCEPHALITIS; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; GENE SILENCING; HUMAN; IMMUNE RESPONSE; INCIDENCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VENEZUELAN EQUINE ENCEPHALITIS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS REPLICATION; WESTERN EQUINE ENCEPHALITIS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

EASTERN EQUINE ENCEPHALITIS VIRUS; EQUIDAE; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; WESTERN EQUINE ENCEPHALOMYELITIS VIRUS;

EID: 84879754914     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.42     Document Type: Review

References (104)

1. Sidwell RW, Smee DF. Viruses of the Bunya-and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res. 57, 101-111 (2003).
2. Calisher CH. Medically important arboviruses of the United States and Canada. Clin. Microbiol. Rev. 7, 89-116 (1994).
3. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58, 491-562 (1994).
4. Weaver SC, Frey TK, Huang UV et al. Family Togaviridae. In: Virus Taxonomy: Classification and Nomenclature of Viruses. Eighth Report of the International Committee on Taxonomy and Nomenclature of Viruses. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (Eds). Academic Press, CA, USA, 999-1008 (2005).
5. Kuhn RJ. Togaviridae: the viruses and their replication, In: Fields Virology (5th Edition). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, NY, USA, 1001-1022 (2007).
6. Griffin DE. Alphaviruses. In: Fields Virology (5th Edition). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, NY, USA, 1023-1067 (2007).
7. Hanson RP. An epizootic of equine encephalomyelitis that occurred in Massachusetts in 1831. Am. J. Trop. Med. Hyg. 6, 858-862 (1957).
8. Zacks MA, Paessler S. Encephalitic alphaviruses. Vet. Microbiol. 140, 281-286 (2010).
9. Hahn CS, Lustig S, Strauss EG, Strauss JH. Western equine encephalitis virus is a recombinant virus. Proc. Natl Acad. Sci. USA 85, 5997-6001 (1988).
10. Reisen WK, Monath TP. Western equine encephalomyelitis. In: The Arboviruses: Epidemiology and Ecology (Volume V). Monath TP (Ed.). CRC Press, FL, USA, 89-137 (1988).
11. Fleming D, Hunt D. Biological Safety: Principles and Practices (4th Edition). ASM Press, Washington, DC, USA (2006).
12. Fothergill LD, Holden M, Wyckoff RWG et al. Western equine encephalomyelitis in a
13. laboratory worker. JAMA 113, 206-207 (1939).
14. Rivas F, Diaz LA, Cardenas VM et al. Epidemic Venezuelan equine encephalitis in La Guajira, Columbia, 1995. J. Infect. Dis. 175, 828-832 (1997).
15. Casals J, Curnen EC, Thomas L. Venezuelan equine encephalomyelitis in man. J. Exp. Med. 77, 521-530 (1943).
16. Lennette EH, Koprowski H. Human infection with Venezuelan equine encephalomyelolitis virus: a report on eight cases of infection acquired in the laboratory. JAMA 13, 1088-1095 (1943).
17. Koprowski H, Cox HR. Human laboratory infection with Venezuelan equine encephalitis virus. N. Engl. J. Med. 236, 647-654 (1947).
18. Jarling PB, Navarro E, Scherer WF. Interferon induction and sensitivity as correlates to virulence of Venezuelan equine encephalitis viruses for hamsters. Arch. Virol. 51, 23-35 (1976).
19. Liang XH, Goldman JE, Jiang HH et al. Resistance of interleukin 1b deficient mice to fatal Sindbis virus encephalitis. J. Virol. 73, 2563-2567 (1999).
20. Griffin DE, Johnson RT. Role of the immune response in recovery from Sindbis virus encephalitis in mice. J. Immunol. 118, 1070-1075 (1977).
21. Griffin D, Levine B, Tyor W et al. The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159, 155-161 (1997).
22. Brookes CB, Deming DJ, Whitmore AC et al. T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalitis in the absence of antibody. J. Virol. 84, 4556-4568 (2010).
23. Elvin SJ, Bennett AM, Phillpotts RJ. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J. Med. Virol. 67, 384-393 (2002).
24. Casadevall A, Pirofski LA. New concepts in antibody-mediated immunity. Infect. Immunol. 72, 6191-6196 (2004).
25. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Ann. Rev. Cell Dev. Biol. 12, 181-220 (1996).
26. Bregenholt S, Haurum J. Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin. Biol. Ther. 4, 387-396 (2004).
27. Casadevall A, Pirofski LA. The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin. Biol. Ther. 5, 1359-1372 (2005).
28. Sabin AB. Quantitative studies on prophylactic effectiveness of western equine encephalitis antiserum in mice. Proc. Soc. Exp. Biol. Med. 78, 655-658 (1951).
29. Cremer NE, Lennette EH, Hagens SJ, Fujimoto FY. Difference in mechanism of viral neutralization under in vitro and in vivo conditions. J. Immunol. 96, 284-288 (1966).
30. Rabinowitz SG, Adler WH. Host defenses during primary Venezuelan equine encephalomyelitis virus infection in mice. I. Passive transfer of protection with immune serum and immune cells. J. Immunol. 110, 1345-1353 (1973).
31. Brown A, Officer JE. An attenuated variant of eastern encephalitis virus: biological properties and protection induced in mice. Arch. Virol. 47, 123-138 (1975).
32. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602-614 (2000).
33. Mathews JH, Roehrig JT. Determination of the protective epitopes on the glycoprotein of Venezuelan equine encephalitis virus by passive transfer of monoclonal antibodies. J. Immunol. 129, 2763-2767 (1982).
34. Roehrig JT, Mathews JH. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 142, 347-356 (1985).
35. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J. Immunother. 15, 42-52 (1994).
36. Phillpotts RJ, Jones LD, Howard SC. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 20, 1497-1504 (2002).
37. Roehrig JT, Day JW, Kinney RM. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 118, 269-278 (1982).
38. Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl. Trop. Dis. 4, e739 (2010).
39. Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297, 70-72 (1982).
40. Phillpotts RJ. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res. 120, 107-112 (2006).
41. Rulker T, Voss L, Thullier P et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS ONE 7, e37242 (2012).
42. Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D, Hart MK. Antibody to the E3 glycoprotein protects mice against lethal Venezuelan equine encephalitis virus infection. J. Virol. 84, 12683-12690 (2010).
43. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q. J. Nucl. Med. Mol. Imaging 48, 251-257 (2004).
44. Gussow D, Seemann G. Humanization of monoclonal antibodies. Methods Enzymol. 203, 99-121 (1991).
45. Hunt AR, Frederickson S, Hinkel C et al. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalitis virus. J. Gen. Virol. 87, 2467-2476 (2006).
46. Hu WG, Chau D, Wu J, Jager S, Nagata LP. Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 25, 3210-3214 (2007).
47. Hu WG, Phelps AL, Jager S et al. A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine 28, 5558-5564 (2010).
48. Goodchild SA, O'Brien LM, Steven J et al. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res. 90, 1-8 (2011).
49. O'Brien LM, Goodchild SA, Phillpotts RJ, Perkins SD. A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge. Virology 426, 100-105 (2012).
50. Schafer A, Brooke CB, Whitmore AC, Johnston RE. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J. Virol. 85, 10682-10690 (2011).
51. Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, Blair CD. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 414, 146-152 (2011).
52. Thullier P, Huish O, Pelat T, Martin AC. The humanness of macaque antibody sequences. J. Mol. Biol. 396, 1439-1450 (2010).
53. Sadler AJ, Williams RG. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559-568 (2008).
54. Borden EC, Sen GC, Uze G et al. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6, 975-990 (2007).
55. Lukaszewski RA, Brooks TJ. Pegylated a interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has a profound effect on the host immune response to infection. J. Virol. 74, 5006-5015 (2000).
56. Julander JG, Siddharthan V, Blatt LM, Schafer K, Sidwell RW, Morey JD. Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model. Virology 360, 454-460 (2007).
57. Wu JQ, Barabe ND, Huang YM et al. Pre- and post-exposure protection against western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 369, 206-213 (2007).
58. O'Brien L, Perkins S, Williams A et al. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J. Gen. Virol. 90(4), 874-882 (2009).
59. Han Q, Zhang C, Zhang J, Tian Z. Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS ONE 6(12), e27931 (2011).
60. Paessler S, Rijinbrand R, Stein DA et al. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 376, 357-370 (2008).
61. Iversen PL. Chapter 20. Morphinos. In: Antisense Drug Technology: Principles, Strategies and Applications (2nd Edition). Crooke ST (Ed.). CRC Press, Taylor and Francis Group, FL, USA, 565-579 (2008).
62. O'Brien L. Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs. Antiviral Res. 75, 20-25 (2007).
63. Logue CH, Phillips AT, Mossel EC et al. Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal western equine encephalitis virus (WEEV) challenge. Antiviral Res. 87, 195-203 (2010).
64. Wong JP, Christopher ME. Broad-spectrum drugs against viral agents. Int. J. Mol. Sci. 9, 1561-1594 (2008).
65. Stephen EL, Hilmas DE, Levy HB et al. Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic- polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J. Infect. Dis. 139, 267-272 (1979).
66. Wong JP, Nagata LP, Christopher ME et al. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 23, 2266-2268 (2005).
67. Barber TL, Walton TE, Lewis KJ. Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses. Am. J. Vet. Res. 39, 621-625 (1978).
68. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14(4), 337-343 (1996).
69. Hoke CH Jr. History of U.S. military contributions to the study of viral encephalitis. Mil. Med. 170, 92-105 (2005).
70. Paessler S, Weaver SC. Vaccines for Venezuelan equine encephalitis. Vaccine 27(Suppl. 4), D80-D85 (2009).
71. Spurgers KB, Glass PJ. Vaccine development for biothreat alphaviruses. J. Bioterr. Biodef. S1, 001 (2011).
72. Davis NL, Brown KW, Greenwald GF et al. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212, 102-110 (1995).
73. Pratt WD, Davis NL, Johnston RE, Smith JF. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21, 3854-3862 (2003).
74. Fine DL, Roberts BA, Teehee ML et al. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 25, 1868-1876 (2007).
75. Reed DS, Lind CM, Lackemeyer MG et al. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine 23, 3139-3147 (2005).
76. Ludwig GV, Turell MJ, Vogel P et al. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am. J. Trop. Med. Hyg. 64, 49-55 (2001).
77. Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 26, 3497-3506 (2008).
78. Martin SS, Bakken RR, Lind CM et al. Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine. Vaccine 27, 6814-6823 (2009).
79. Martin SS, Bakken RR, Lind CM et al. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 28, 3143-3151 (2010).
80. Paessler S, Fayzulin RZ, Anishchenko M et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J. Virol. 77, 9278-9286 (2003).
81. Paessler S, Ni H, Petrakova O et al. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J. Virol. 80, 2784-2796 (2006).
82. Wang E, Petrakova O, Adams AP et al. Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine 25, 7573-7581 (2007).
83. Roy CJ, Adams AP, Wang E et al. A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus. Vaccine 31, 1458-1463 (2013).
84. Atasheva S, Wang E, Adams AP et al. Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus. Vaccine 27, 4309-4319 (2009).
85. Dupuy LC, Schmaljohn CS. DNA vaccines for biodefense. Expert Rev. Vaccines 8, 1739-1754 (2009).
86. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan equine encephalitis virus. Vaccine 18, 588-596 (2000).
87. Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21, 4071-4080 (2003).
88. Dupuy LC, Richards MJ, Reed DS et al. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 28, 7345-7350 (2010).
89. Dupuy LC, Richards MJ, Ellefsen B et al. A DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin. Vaccine Immunol. 18, 707-716 (2011).
90. Nagata LP, Hu WG, Masri SA et al. Efficacy of DNA vaccination against western equine encephalitis virus infection. Vaccine 23, 2280-2283 (2005).
91. Gauci PJ, Wu JQ, Rayner GA, Barabe ND, Nagata LP, Proll DF. Identification of western equine encephalitis virus structural proteins that confer protection after DNA vaccination. Clin. Vaccine Immunol. 17, 176-179 (2010).
92. Wu JQ, Barabe ND, Chau D et al. Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine. Vaccine 25, 4368-4375 (2007).
93. Barabe ND, Rayner GA, Christopher ME, Nagata LP, Wu JQ. Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus. Vaccine 25(33), 6271-6276 (2007).
94. Swayze RD, Bhogal HS, Barabe ND, McLaws LJ, Wu JQ. Envelope protein E1 as vaccine target for western equine encephalitis virus. Vaccine 29, 813-820 (2011).
95. Kinney RM, Esposito JJ, Mathews JH et al. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J. Virol. 62, 4697-4702 (1988).
96. Phillpotts RJ, O'Brien L, Appleton RE et al. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 23, 1615-1623 (2005).
97. Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis. Nature 218, 1057-1059 (1968).
98. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149-1176 (2010).
99. Akahata W, Yang ZY, Andersen H et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334-338 (2010).
100. Peiperl L, Morgan C, Moodie Z et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5- seronegative persons: a randomized clinical trial (HVTN 054). PLoS ONE 5(10), e13579 (2010).
101. Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3(10), e3548 (2008).
102. Landry N, Ward BJ, Trepanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010).
103. Metcalf TU, Griffin DE. Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J. Virol. 85(21), 11490-11501 (2011).
104. Kehn-Hall K, Narayanan A, Lundberg L et al. Modulation of GSK-3b activity in Venezuelan equine encephalitis virus infection. PLoS ONE 7(4), e34761 (2012).